Correlation Between Zenas BioPharma, and GRI Bio

Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and GRI Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and GRI Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zenas BioPharma, Common and GRI Bio, you can compare the effects of market volatilities on Zenas BioPharma, and GRI Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of GRI Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and GRI Bio.

Diversification Opportunities for Zenas BioPharma, and GRI Bio

-0.02

Correlation Coefficient

Zenas BioPharma,  GRI Bio

Good diversification

The 3 months correlation between Zenas and GRI is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and GRI Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GRI Bio and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with GRI Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GRI Bio has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and GRI Bio go up and down completely randomly.

Pair Corralation between Zenas BioPharma, and GRI Bio

Given the investment horizon of 90 days Zenas BioPharma, Common is expected to generate 0.49 times more return on investment than GRI Bio. However, Zenas BioPharma, Common is 2.03 times less risky than GRI Bio. It trades about -0.12 of its potential returns per unit of risk. GRI Bio is currently generating about -0.07 per unit of risk. If you would invest  1,815  in Zenas BioPharma, Common on September 21, 2024 and sell it today you would lose (839.00) from holding Zenas BioPharma, Common or give up 46.23% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	13.94%
Values	Daily Returns

Zenas BioPharma, Common  vs.  GRI Bio

Zenas BioPharma, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

GRI Bio

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in GRI Bio are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, GRI Bio demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zenas BioPharma, and GRI Bio

The main advantage of trading using opposite Zenas BioPharma, and GRI Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, GRI Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GRI Bio will offset losses from the drop in GRI Bio's long position.

The idea behind Zenas BioPharma, Common and GRI Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.